Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles

International Journal of Pharmaceutics

Volumn 447, Issue 1-2, 2013, Pages 62-69

  Kouchakzadeh, Hasan ^a   Shojaosadati, Seyed Abbas ^a   Tahmasebi, Fathollah ^b   Shokri, Fazel ^b,c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

1F2 monoclonal antibody; Active targeting; ELISA; Flow cytometry; Human serum albumin nanoparticles; In vitro cytotoxicity

Indexed keywords

2 IMINOTHIOLANE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1F2; NANOPARTICLE; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL ADHESION; CONTROLLED STUDY; CROSS LINKING; DISULFIDE BOND; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PARTICLE SIZE; PRIORITY JOURNAL; REACTION TIME; ZETA POTENTIAL;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-2; SERUM ALBUMIN;

EID: 84874940184     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.02.043     Document Type: Article

References (28)

1. S. Acharya, F. Dilnawaz, and S.K. Sahoo Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy Biomaterials 30 2009 5737 5750
2. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2 2002 750 763
3. M.G. Anhorn, S. Wagner, J. Kreuter, K. Langer, and H.V. Briesen Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles Bioconjug. Chem. 19 2008 2321 2331
4. M.G. Anhorn, H.C. Mahler, and K. Langer Freeze drying of human serum albumin (HSA) nanoparticles with different excipients Int. J. Pharm. 363 2008 162 169
5. E. Barrajon-Catalan, M.P. Menendez-Gutierrez, A. Falco, A. Carrato, M. Saceda, and V. Micol Selective death of human breast cancer cells by lytic immunoliposomes: correlation with their HER2 expression level Cancer Lett. 290 2010 192 203
6. A. Cirstoiu-Hapca, L. Bossy-Nobs, F. Buchegger, R. Gurny, and F. Delie Differential tumor cells targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles Int. J. Pharm. 331 2007 190 196
7. F. Danhier, O. Feron, and V. Preat To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Control. Release 148 2010 135 146
8. S. Dreis, F. Rothweiler, M. Michaels, J. Cinatl Jr.; J. Kreuter, and K. Langer Preparation, characterization and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles Int. J. Pharm. 341 2007 207 214
9. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
10. X. Han, J. Liu, M. Liu, C. Xie, C. Zhang, B. Gu, Y. Liu, L. Feng, and W. Lu 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro Int. J. Pharm. 372 2009 125 131
11. H. Hatakeyama, H. Akita, E. Ishida, K. Hashimoto, H. Kobayashi, T. Aoki, J. Yasuda, K. Obata, H. Kikuchi, T. Ishida, H. Kiwada, and H. Harashima Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes Int. J. Pharm. 342 2007 194 200
12. J.M. Irache, and S. Espuelas Biological and Pharmaceutical Nanomaterials 2006 Wiley New York
13. T. Kazemi, F. Tahmasebi, A. Bayat, N. Mohajer, J. Khoshnoodi, M. Jeddi-Tehrani, H. Rabbani, and F. Shokri Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor Hybridoma 30 2011 347 353
14. P. Kocbek, N. Obermajer, M. Cegnar, J. Kos, and J. Kristl Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody J. Control. Release 120 2007 18 26
15. H. Kouchakzadeh, S.A. Shojaosadati, A. Maghsoudi, and E. Vasheghani Farahani Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology AAPS PharmSciTech 11 2010 1206 1211
16. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
17. T. Lammers, F. Kissling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187
18. K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H.V. Briesen, and D. Schubert Optimization of the preparation process for human serum albumin (HSA) nanoparticles Int. J. Pharm. 257 2003 169 180
19. K. Langer, M.G. Anhorn, I. Steinhauser, S. Dreis, D. Celebi, N. Schrickel, V. Faust, and V. Vogel Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation Int. J. Pharm. 347 2008 109 117
20. X. Li, L. Ding, Y. Xu, Y. Wang, and Q. Ping Targeted delivery of doxorubicin using stealth liposomes modified with transferrin Int. J. Pharm. 373 2009 116 123
21. A. Maghsoudi, S.A. Shojaosadati, and E. Vasheghani Farahani 5-Fluorouracil-loaded BSA nanoparticles: formulation optimization and in vitro release study AAPS PharmSciTech 9 2008 1092 1096
22. F. Marcucci, and L. Lefoulon Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress Drug Discov. Today 9 2004 219 228
23. G.V. Patil Biopolymer albumin for diagnosis and in drug delivery Drug Dev. Res. 58 2003 219 247
24. I. Steinhauser, B. Spankuch, K. Strebhardt, and K. Langer Trastuzumab-modified nanoparticles: optimization of preparation and uptake in cancer cells Biomaterials 27 2006 4975 4983
25. I.M. Steinhauser, K. Langer, K.M. Strebhardt, and B. Spankuch Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation Biomaterials 29 2008 4022 4028
26. W. Tai, R. Mahato, and K. Cheng The role of HER2 in cancer therapy and targeted drug delivery J. Control. Release 146 2010 264 275
27. V.P. Torchilin Passive and active drug targeting: drug delivery to tumors as an example M. Schafer-Korting, Handbook of Experimental Pharmacology vol. 197 2010 Springer-Verlag Berlin, Heidelberg 3 53
28. S. Wagner, F. Rothweiler, M.G. Anhorn, D. Sauer, I. Riemann, E.C. Weiss, A. Kasten-Globa, M. Michaelis, J. Cindrich Jr.; D. Schwartz, J. Kreuter, H.V. Briesen, and LangerF K. Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles Biomaterials 31 2010 2388 2398